PhoreMost closes GBP33m Series B financing
PhoreMost, a UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable’, disease targets, has completed an oversubscribed GBP33 million (USD46 million) Series B investment round. The round was led by BGF, the UK’s most active growth economy investor, and included new investors XtalPi Inc, Astellas Venture Management, Trend Investment Group and